Innovative Once-Weekly Injection Demonstrates Potential for Managing Diabetes and Facilitating Weight Loss
A new once-weekly injection, ecnoglutide, shows promising results for effectively managing blood sugar levels and promoting weight loss in adults with type 2 diabetes, offering a potential new treatment option.
A recent breakthrough in diabetes treatment involves a novel medication, ecnoglutide, administered as a once-weekly injection. In a comprehensive phase 3 clinical trial, ecnoglutide was found to be as effective as dulaglutide—another once-weekly drug—in reducing blood sugar levels in adults with type 2 diabetes. Notably, patients receiving ecnoglutide experienced greater weight loss compared to those on dulaglutide, with an average weight reduction of approximately 5.2% to 5.7%, versus 2.8% in the dulaglutide group.
The study, which spanned a year and involved over 600 participants in China, measured the decline in blood glucose levels and weight loss, revealing that ecnoglutide lowered blood sugar by about 1.9%, slightly surpassing the 1.65% reduction seen with dulaglutide. The medication operates by targeting the GLP-1 receptor, enhancing insulin secretion and reducing blood sugar levels, while selectively activating certain pathways to improve efficacy and minimize side effects.
Patients tolerated ecnoglutide well, with mild gastrointestinal symptoms such as nausea and diarrhea that generally diminished over time. Additionally, manufacturing advantages of ecnoglutide suggest it may be produced more cost-effectively than existing GLP-1 receptor agonists, potentially increasing accessibility.
Experts consider this promising development as a dual-purpose therapy that not only effectively controls blood sugar but also promotes significant weight loss, both critical in reducing cardiovascular risks associated with type 2 diabetes. Further research is needed to confirm these benefits across diverse populations and in combination with other treatments.
Source: https://medicalxpress.com/news/2025-08-week-dual-diabetes-weight-loss.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Oral Delivery System Could Replace Injections for Protein-Based Drugs
A novel oral delivery system developed by the University of Bath could enable protein-based medications to be taken as pills, replacing painful injections and improving patient compliance.
Regional Variations in COVID-19 Deaths Across Europe During 2020 and 2021
An in-depth look at how COVID-19 caused significant regional differences in mortality across Europe during 2020 and 2021, emphasizing the importance of localized health data.
Innovative Technology Identifies Breast Cancer Relapses up to Five Years Early
A novel blood test developed by Altum Sequencing can predict breast cancer relapse up to five years in advance, revolutionizing post-treatment monitoring and early intervention strategies.
Research Highlights Significant Health Insurance Gaps Among Adopted Children in the U.S.
A recent study reveals significant disparities in health insurance coverage among adopted children in the U.S., particularly affecting international adoptees and children of non-citizen adoptive parents. Understanding these gaps is crucial for targeted policy reforms to ensure equitable healthcare access.